medac Group Expands European Pharmaceutical Manufacturing with New Production Line

• medac Group has launched a new high-performance pharmaceutical production line at oncomed manufacturing a.s. in Brno, Czech Republic, focused on the high-quality manufacturing of prefilled syringes and cartridges.

• This investment, exceeding CZK 1 billion, will enable the production of over 100 million prefilled syringes annually, primarily for autoimmune disease treatments.

medac Group has officially launched its third production line at oncomed manufacturing a.s. in Brno, Czech Republic, marking a key milestone in its expansion of pharmaceutical manufacturing capabilities. The new line, designed for the high-quality production of prefilled syringes and cartridges, is the first of its kind in both the Czech Republic and Slovakia. This move is part of medac Group’s broader strategy to strengthen the European pharmaceutical production infrastructure.

The total investment for the new line exceeds CZK 1 billion, supported by an incentive of CZK 203 million from the Czech government. The line will allow for the annual production of over 100 million prefilled syringes, catering primarily to patients with autoimmune conditions like rheumatoid arthritis, psoriasis, and Crohn’s disease. This investment is expected to meet the growing global demand for such injectable treatments within the next two years.

The grand opening ceremony was attended by several notable figures, including Minister of Health Vlastimil Válek and the Mayor of Brno, Markéta Vaňková. The event highlighted the importance of this investment in reinforcing the region’s pharmaceutical capabilities, contributing to the European self-sufficiency in critical treatments. The opening also marked the creation of more than 30 new jobs, enhancing medac Group’s position as a significant regional employer.